Unknown PHASE2 INTERVENTIONAL 1-arm NCT05588297

Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases

Safety and Efficacy of Nivolumab Combined With CAPOX Plus Bevacizumab as Neoadjuvant Treatment of pMMR/MSS Colorectal Cancer Liver Metastases Patients：a Single-arm, Phase II, Prospective Study

Sponsor: Shanghai Changzheng Hospital

Conditions Colorectal Cancer Liver Metastases

Interventions Bevacizumab CapOx(Capecitabine+ Oxaliplatin) Nivolumab

Updated 4 times since 2022 Last updated: Oct 18, 2022 Started: Oct 31, 2022 Primary completion: Mar 31, 2023 Completion: Oct 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05588297, this PHASE2 trial focuses on Colorectal Cancer Liver Metastases and remains ongoing. Sponsored by Shanghai Changzheng Hospital, it has been updated 4 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Dec 2025 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Nov 2022 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Oct 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai Changzheng Hospital

Data source: Shanghai Changzheng Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.